Derek Archila analyst WELLS FARGO

Currently out of the existing stock ratings of Derek Archila, 286 are a BUY (68.26%), 120 are a HOLD (28.64%), 13 are a SELL (3.1%).

Derek Archila

Work Performance Price Targets & Ratings Chart

Analyst Derek Archila, currently employed at WELLS FARGO, carries an average stock price target met ratio of 52.62% that have a potential upside of 51.02% achieved within 272 days.

Derek Archila’s has documented 814 price targets and ratings displayed on 69 stocks. The coverage is on Healthcare, Energy, Technology, Financial Services sectors.

Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals.

Wall Street Analyst Derek Archila

Analyst best performing recommendations are on EQ (EQUILLIUM).
The best stock recommendation documented was for EQ (EQUILLIUM) at 7/10/2020. The price target of $10 was fulfilled within 3 days with a profit of $6.81 (213.48%) receiving and performance score of 711.6.

Average potential price target upside

AIMT Aimmune Therapeutics AMRN Amarin PLC ASND Ascendis Pharma AS CBAY Cymabay Therapeu IMVT Immunovant KZR Kezar Life Sciences MNTA Momenta Pharmaceuticals PCRX Pacira Pharmaceuticals RYTM Rhythm Pharmaceuticals SGYP Synergy Pharmaceuticals VNDA Vanda Pharmaceuticals GLPG Galapagos NV ADR ICPT Intercept Pharmaceuticals NGM NGM Biopharmaceuticals PHAS PhaseBio Pharmaceuticals PRNB Principia Biopharma APLS Apellis Pharmaceuticals ARVN Arvinas CCCC C4 Therapeutics HZNP Horizon Pharma PLC INCY yte KYMR Kymera Therapeutics NRIX Nurix Therapeutics CABA Cabaletta Bio GLUE Monte Rosa Therapeutics MORF Morphic ARGX argenx NV ADR RXDX Prometheus Biosciences URGN UroGen Pharma Ltd ARNA Arena Pharmaceuticals BPMC Blueprint Medicines Corp ESPR Esperion Therapeutics HRTX Heron Therapeuti TEVA Teva Pharma Industries Ltd ADR ZYNE Zynerba Pharmaceuticals CLDX Celldex Therapeutics DICE Dice Molecules Holdings LLC MOR MorphoSys AG ADR VTYX Ventyx Biosciences ZNTL Zentalis Pharmaceuticals Llc ANAB AnaptysBio ANNX Annexon EXEL Exelixis VRDN Viridian Therapeutics ZYME Zymeworks SLRN ACELYRIN, INC. CQP Cheniere Energy Partners LP EQ Equillium STRO Sutro Biopharma ALNY Alnylam Pharmaceuticals BBIO BridgeBio Pharma ORIC Oric Pharmaceuticals PRGO Perrigo Company PLC SLNO Soleno Therapeutics AI C3 Ai ALMS Alumis ALXN Alexion Pharmaceuticals BP BP PLC ADR CB Chubb Ltd DBVT DBV Technologies IRON Disc Medicine IVA Inventiva Sa KYTX Kyverna Therapeutics LUMO Lumos Pharma SEPN Septerna PYXS Pyxis Oncology QTTB Q32 Bio VKTX Viking Therapeutics SELB Selecta Biosciences

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 19-Dec-2019

$18

6 years 1 months 19 days ago
(01-Sep-2020)

3/3 (100%)

$3.19 (21.54%)

78

Buy Since 17-Nov-2015

$35

$0.51 (1.48%)

6 years 1 months 19 days ago
(31-Aug-2020)

5/14 (35.71%)

$0.78 (2.28%)

488

Hold Since 04-Feb-2020

$34.5

$0.01 (0.03%)

6 years 1 months 19 days ago
(31-Aug-2020)

5/5 (100%)

$0.28 (0.82%)

138

Buy Since 14-Jun-2016

$34.5

$0.01 (0.03%)

$66

6 years 1 months 19 days ago
(31-Aug-2020)

1/9 (11.11%)

$0.28 (0.82%)

39

Buy Since 03-Jun-2019

$60

6 years 1 months 19 days ago
(31-Aug-2020)

0/19 (0%)

$41.31 (221.03%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Derek Archila most bullish on?

Potential upside of $536.86 has been obtained for ARGX (ARGENX NV ADR)

Which stock is Derek Archila most reserved on?

Potential downside of $0.58 has been obtained for NRIX (NURIX THERAPEUTICS)

What Year was the first public recommendation made by Derek Archila?

On 2016
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?